Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Stellar Presents Preclinical Poster on C. diff Active Immunotherapy

Published: Tuesday, October 29, 2013
Last Updated: Tuesday, October 29, 2013
Bookmark and Share
Poster presented at 7th Vaccine and ISV Congress being held in Spain.

Stellar Biotechnologies, Inc. has announced the presentation of a preclinical poster at the 7th Vaccine and ISV Congress being held in Sitges, Spain, October 27-29, 2013.

The presentation relates to a recent study in mice of Stellar’s newly acquired active immunotherapy technology targeting the treatment of Clostridium difficile infection (“C. diff”).

Clostridium difficile is a bacteria found in the intestines that can cause severe and life-threatening intestinal conditions. C. diff infections are at an all-time high and related hospitalizations have tripled in the last decade.

The poster titled “Immunization with Clostridium difficile PSII Polysaccharide Antigens Adjuvanted with KLH Induced Broad-based Enhancement of Adaptive Immune Responses and Protection in Mice” is the result of preclinical research conducted together by scientists from Stellar and the University of Guelph (Ontario, Canada) (“Guelph”).

In the study, vaccination with a PSII-KLH conjugate vaccine conferred protection against C. diff infection, measured by improved survival rates in vaccinated mice compared to unvaccinated controls.

The study concluded that the C. diff PSII-KLH immunotherapy approach was safe and efficacious in a preclinical model. Further preclinical development is underway.

The 7th Vaccine & ISV Congress features science and public health topics, from primary vaccine research and vaccine manufacturers, to governmental policy, safety and regulation.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Stellar Announces Issuance of Patents for C. diff Immunotherapy Technology
Issuance of two additional patents in U.S. and China.
Tuesday, December 10, 2013
Stellar’s Immunotherapy Technology Demonstrates Protection Against C. diff Infection
Study results presented this week at ClostPath 8 in Australia, October 22-26, 2013.
Tuesday, October 22, 2013
Stellar Acquires Exclusive, Worldwide License to C. diff Immunotherapy Technology
Stellar expands with proprietary KLH-based vaccine program.
Wednesday, July 31, 2013
Stellar Announces New Board Members
Appointment of Gregory T. Baxter and Mike Sampat to Board.
Wednesday, August 22, 2012
Stellar Announces Chow and Brisson to New C-Level Posts
Herbert S. Chow and Catherine Brisson appointed to the position of CTO and CPO respectively.
Tuesday, August 14, 2012
Stellar Announces Exclusive Option to License Clostridium Difficile Technology
Stellar executes agreement with University of Guelph for vaccine research.
Wednesday, April 11, 2012
Stellar Biotechnologies Announces Investor Relations Agreement
Stellar Biotechnologies, Inc. is pleased to announce that it has retained TheBiotechPanel, Inc. to provide the Company with investor relations services, for an initial period of six months.
Wednesday, January 18, 2012
Stellar Biotechnologies Announces a Strategic Agreement for Marketing and Sales with SAFC®
Stellar will produce KLH commercial intermediate and SAFC will sell, distribute and market cGMP-grade HMW KLH.
Friday, August 05, 2011
Stellar Biotechnologies Announces Appointment of New Director, David L. Hill, Ph. D.
Dr. Hill, is a Board Certified High Complexity Laboratory Director, Board Certified Embryology Laboratory Director and member of the American Association of Bioanalysts.
Friday, May 27, 2011
Stellar Biotechnologies Appoints Vice President, Business Development & Marketing
Company Executive VP, Darrell Brookstein's title will be changed to Executive VP, Corporate Development & Finance.
Wednesday, March 09, 2011
Scientific News
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
Researchers Develop Vaccine that Protects Primates Against Ebola
A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.
Universal Flu Vaccine in the Works
A new study has demonstrated a potential strategy for developing a flu vaccine with potent, broad protection.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Ferring Bets on Bacteriophages to Treat Inflammatory Bowel Disease
Ferring Pharmaceuticals have annoucned that it will collaborate with Intralytix in the latest phase of its early stage development programme for a bacteriophage-based therapy for inflammatory bowel disease (IBD).
A Novel Drug to FIght Malaria
An international team of scientists has announced that a new compound to fight malaria is ready for human trials.
Ebola Vaccine Trial Begins in Senegal
A clinical trial to evaluate an Ebola vaccine has begun in Dakar, Senegal, after initial research started at the Jenner Institute, Oxford University.
New Cell Structure Finding Might Lead to Novel Cancer Therapies
University of Warwick scientists in the U.K. say they have discovered a cell structure which could help researchers understand why some cancers develop.
Cancer Discovery Links Experimental Vaccine and Biological Treatment
A new study at the University of Wisconsin-Madison has linked two seemingly unrelated cancer treatments that are both now being tested in clinical trials.
Study Reveals New Method to Develop More Efficient Drugs
A new study suggests a new approach to develop highly-potent drugs which could overcome current shortcomings of low drug efficacy and multi-drug resistance in the treatment of cancer as well as viral and bacterial infections.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!